ONCOLYTICS BIOTECH INC
About ONCOLYTICS BIOTECH INC
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$28.8M
- Total assets
- $7.6M
- Market cap
- $99.8M
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $28.7M
- Operating income
- -$28.7M
- Income tax
- $79.0K
- Net income
- -$28.8M
- EPS (basic)
- $-0.30
- EPS (diluted)
- $-0.30
Balance sheet
- Total assets
- $7.6M
- Current assets
- $6.8M
- Total liabilities
- $11.4M
- Current liabilities
- $6.1M
- Shareholders’ equity
- -$3.8M
Cash flow
- Operating cash flow
- -$20.1M
- Investing cash flow
- -$6.0K
- Financing cash flow
- $14.1M
- Net cash flow
- -$5.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $99.8M
- EPS (diluted)
- $-0.3
- Shares outstanding
- 118.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 5, 2001
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $28.8M.
- Trading 41% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ONCOLYTICS BIOTECH INC.
Write a review
News about ONCOLYTICS BIOTECH INC
News & sentiment via Polygon.io
